Echizen H - Search Results

1

Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Echizen H, Eichelbaum M. Echizen H, et al. Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002. Clin Pharmacokinet. 1986. PMID: 3542336 Review.

2

Clinical pharmacokinetics of famotidine.

Echizen H, Ishizaki T. Echizen H, et al. Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. Clin Pharmacokinet. 1991. PMID: 1764869 Review.

3

An interindividual variability in the sensitivity of atrioventricular node to diltiazem in patients with paroxysmal supraventricular tachycardia.

Fukuhara S, Echizen H, Naito M, Ishikawa S, Toyama M, Nagoshi H, Honda M, Ishizaki T. Fukuhara S, et al. Among authors: echizen h. J Clin Pharmacol. 1989 Feb;29(2):102-6. doi: 10.1002/j.1552-4604.1989.tb03294.x. J Clin Pharmacol. 1989. PMID: 2715366

4

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H. Takahashi H, et al. Among authors: echizen h. Clin Pharmacokinet. 2001;40(8):587-603. doi: 10.2165/00003088-200140080-00003. Clin Pharmacokinet. 2001. PMID: 11523725 Review.

5

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. Vogelgesang B, et al. Among authors: echizen h. Br J Clin Pharmacol. 1984 Nov;18(5):733-40. doi: 10.1111/j.1365-2125.1984.tb02536.x. Br J Clin Pharmacol. 1984. PMID: 6508982 Free PMC article.

6

Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Horai Y, Ishizaki T, Sasaki T, Chiba K, Suganuma T, Echizen H, Ohnishi A. Horai Y, et al. Among authors: echizen h. Eur J Clin Pharmacol. 1983;24(1):79-87. doi: 10.1007/BF00613931. Eur J Clin Pharmacol. 1983. PMID: 6832206 Clinical Trial.

7

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

Echizen H, Vogelgesang B, Eichelbaum M. Echizen H, et al. Clin Pharmacol Ther. 1985 Jul;38(1):71-6. doi: 10.1038/clpt.1985.137. Clin Pharmacol Ther. 1985. PMID: 4006378 Clinical Trial.

8

Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Yoshimoto K, et al. Among authors: echizen h. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. doi: 10.1111/j.1365-2125.1995.tb04472.x. Br J Clin Pharmacol. 1995. PMID: 7640150 Free PMC article.

9

Electrophysiologic effects of dextro- and levo-verapamil on sinus node and AV node function in humans.

Echizen H, Manz M, Eichelbaum M. Echizen H, et al. J Cardiovasc Pharmacol. 1988;12(5):543-6. doi: 10.1097/00005344-198811000-00007. J Cardiovasc Pharmacol. 1988. PMID: 2468053

10

Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects.

Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Kroemer HK, et al. Among authors: echizen h. J Pharmacol Exp Ther. 1992 Mar;260(3):1052-7. J Pharmacol Exp Ther. 1992. PMID: 1545377

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results